BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 10:44:00 AM | Browse: 624 | Download: 594
Publication Name World Journal of Anesthesiology
Manuscript ID 5111
Country/Territory Canada
2013-08-16 08:12
Peer-Review Started
2013-08-16 10:39
To Make the First Decision
2013-09-02 16:13
Return for Revision
2013-09-04 16:49
2014-06-06 00:00
Second Decision
2014-06-16 13:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-16 14:11
Articles in Press
2014-06-16 14:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-08-18 21:37
Publish the Manuscript Online
2014-08-20 21:05
ISSN 2218-6182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Anesthesiology
Manuscript Type Autobiography
Article Title Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis
Manuscript Source Invited Manuscript
All Author List Dana A Turcotte, Malcolm Doupe, Mahmoud Torabi, Andrew J Gomori, Karen Ethans, Farid Esfahani, Katie Galloway and Michael P Namaka
Funding Agency and Grant Number
Corresponding author Dr. Dana A Turcotte, Faculty of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, Manitoba R3E 0T5, Canada. danaturcotte19@gmail.com
Key Words Multiple sclerosis; Neuropathic pain; Paroxetine; Pregabalin; Clinical trial
Core Tip The high attrition rates identified in the paroxetine study arm suggest that it be used with caution for multiple sclerosis (MS)-induced neuropathic pain (NPP). Although analysis of the primary endpoint measures revealed no significant differences, there was a trend toward marked improvement for visual analogue scale and daily impact of pain on daily activities in favor of pregabalin. However, due to the premature study cessation, definitive confirmation of pregabalin’s enhanced efficacy was not possible. These results reinforce the recognized challenges clinicians encounter in drug selection for MS-induced NPP. Due to the lack of well-designed controlled NPP trials in this population, effective and well-tolerated treatment selection poses a significant clinical challenge.
Publish Date 2014-08-20 21:05
Citation Turcotte DA, Doupe M, Torabi M, Gomori AJ, Ethans K, Esfahani F, Galloway K, Namaka MP. Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis. World J Anesthesiol 2014; 3(2): 181-188
Url http://www.wjgnet.com/2218-6182/full/v3/i2/181.htm
DOI http://dx.doi.org/10.5313/wja.v3.i2.181
Full Article (PDF) WJA-3-181.pdf
Full Article (Word) WJA-3-181.doc
Manuscript File 5111-Review.docx
Answering Reviewers 5111-Answering reviewers.pdf
Copyright License Agreement 5111-Copyright assignment.pdf
Peer-review Report 5111-Peer review(s).pdf
Scientific Misconduct Check 5111-CrossCheck.jpg
Scientific Editor Work List 5111-Scientific editor work list.pdf